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CancerAbstract Long non-coding RNAs (lncRNAs) play important roles in cancer. They are involved in
chromatin remodeling, as well as transcriptional and post-transcriptional regulation, through a vari-
ety of chromatin-based mechanisms and via cross-talk with other RNA species. lncRNAs can func-
tion as decoys, scaffolds, and enhancer RNAs. This review summarizes the characteristics of
lncRNAs, including their roles, functions, and working mechanisms, describes methods for identi-
fying and annotating lncRNAs, and discusses future opportunities for lncRNA-based therapies
using antisense oligonucleotides.Introduction
Recent advances in sequencing technologies enabling more in-
depth genomic and transcriptomic analyses have revealed that
as much as 85% of the human genome is transcribed [1–3].
This was surprising, as studies of mammalian genomes have
shown that a drastically low population of RNA transcripts
code for protein products. Notably, from the recent Encyclo-
pedia of DNA Elements (ENCODE) work, out of 41,204
called genes, only 56 genes (0.1%) showed mass spectrometricevidence consistent with protein expression, suggesting that the
majority of RNA transcripts are non-coding [4]. The genera-
tion of such a large population of non-coding RNA (ncRNA)
transcripts indicates that RNAs have a larger and more diverse
role in biological processes than initially anticipated. ncRNAs
can be roughly classiﬁed into two groups based on their size.
One group includes short RNAs less than 200 nucleotides
(nt) in length, such as microRNAs (miRNAs) that are small
RNA (sRNA) molecules around 21–24 nt in length, as well
as other classes such as piwi-interacting RNAs (piRNAs) [5].
The other group includes long ncNAs (lncRNAs) of around
200 nt or more [6]. While miRNAs have been heavily studied
and are well understood for their function in gene regulation
[7], lncRNAs in contrast are less understood.
Many lncRNAs have been functionally associated with
human diseases, in particular, cancers [8] (Table 1). Dysregula-
tion of lncRNAs has been implicated in glioblastoma [9–11],nces and
Table 1 Examples of lncRNAs in cancer
lncRNA Description Refs.
PTCSC3 Downregulated in thyroid cancers [82]
HULC Upregulated in hepatocellular carcinoma [81,139–141]
XIST Dysregulated in various cancers [16,142]
GAPLINC Associated with poor prognosis in gastric cancer [143]
MALAT1 Associated with poor prognosis and metastasis in liver, lung and colorectal cancers [144–147]
HOTAIR Associated with metastasis in colorectal, liver, pancreatic, breast and gastric cancers [12–14,148–150]
ANRIL Upregulated in prostate cancer [151]
KCNQ1OT1 Upregulated in colorectal cancer [59]
PRNCR1 Upregulated in prostate cancer [152]
H19 Highly expressed in hepatocellular carcinoma [153]
Fang Y and Fullwood MJ /Long Non-coding RNAs in Cancer 43breast cancer [12], colorectal cancer [9,13], liver cancer [14,15],
and leukemia [9,16]. Commonly, dysregulation of lncRNAs
exerts impacts on cellular functions such as cell proliferation,
resistance to apoptosis, induction of angiogenesis, promotion
of metastasis, and evasion of tumor suppressors [8,17].
An emerging view of lncRNAs is that they are fundamental
regulators of transcription. This view has led to an intense
focus on elucidating the molecular mechanisms that underlie
their function [18]. Many lncRNAs have been characterized
and several models of action have been proposed, such as func-
tioning as signal, decoy, scaffold, guide, enhancer RNAs, and
short peptides [19,20], as mentioned below. The main function
of a signal lncRNA is to serve as a molecular signal to regulate
transcription in response to various stimuli. Thus its produc-
tion and presence can serve as an indicator of transcriptional
activity [21]. Decoy lncRNAs limit the availability of regula-
tory factors by presenting ‘‘decoy” binding sites. These
lncRNAs modulate transcription by sequestering regulatory
factors including transcription factors, catalytic proteins, sub-
units of larger chromatin modifying complexes, as well as miR-
NAs, thereby reducing their availability [22]. Transcripts from
the scaffold class of lncRNAs play a structural role by provid-
ing platforms for assembly of multiple-component complexes,
such as ribonucleoprotein (RNP) complexes [23]. In the case of
RNP complexes, once the complexes have been fully assem-
bled, either transcriptional activation or repression could be
conferred depending on the nature of proteins and RNAs pre-
sent [24,25]. Guide lncRNAs interact with RNPs and direct
them to speciﬁc target genes. These guide lncRNAs are essen-
tial for the proper localization of RNPs [26]. Next, enhancer
RNAs (eRNAs) are produced from enhancer regions and
may work by inﬂuencing the 3-dimensional (3D) organization
of DNA, also known as ‘‘chromatin interactions”. One
hypothesized model of action is that these lncRNAs may pos-
sibly work as ‘‘tethers” as they may not be released from the
enhancer regions when functioning, thus tethering the interact-
ing proteins to enhancer regions [19]. In addition, lncRNAs
can encode short peptides, which may also have functions
[27]. It is likely that additional mechanisms will be discovered
in the future.
This review introduces lncRNAs, focusing on lncRNAs
with cancer-associated roles, and discusses proposed mecha-
nisms by which these lncRNAs function in chromatin remod-
eling, chromatin interactions, and as competing endogenous
RNAs (ceRNAs). In addition, we highlight approaches for
the identiﬁcation and annotation of lncRNAs, cross-talk
between these mechanisms, and methods for perturbingspeciﬁc lncRNAs, which could eventually provide lncRNA-
based therapies for diseases. We then conclude by highlighting
challenges and future research topics.Characteristics of lncRNAs
lncRNAs are deﬁned as RNA molecules with more than 200
nucleotides. This distinction, while somewhat arbitrary and
based on technical aspects of RNA isolation methods, serves
to distinguish lncRNAs from miRNAs and other sRNAs.
lncRNAs are present in large numbers in genome [28,29].
They typically do not possess functional open reading frames
(ORFs). However, this distinction is blurred by the discovery
of bifunctional RNAs that can have both protein-coding and
coding-independent functions [30,31], raising the possibility
that many protein-coding genes may also have non-coding
functions. Many lncRNAs are lowly expressed [32], posing
a challenge in terms of exploration of lncRNAs and explain-
ing why lncRNAs had been thought to be only ‘‘transcrip-
tional noise” until recently. RNA-seq studies in different
tetrapods show that most (81%) lncRNAs are poorly con-
served in DNA sequence and are primate-speciﬁc. However,
it should be noted that several lncRNAs are ultra-conserved
in DNA sequence—3% of lncRNAs appear to have origi-
nated more than 300 million years ago and can be found
from organisms ranging from Xenopus and chicken to man
[33]. It is possible that lncRNAs might be fast-evolving
RNA species that can play key roles in specifying lineages.
In support of this idea, a comparison of matched tissues in
Mus musculus domesticus, Mus musculus castaneus, and Rat-
tus norvegicus shows that the emergence or extinction of
intergenic lncRNAs is associated with changes in transcrip-
tion levels of proximal protein-coding genes [34]. In addition,
there are examples of lncRNAs exhibiting conserved biologi-
cal function but low sequence conservation, such as mega-
mind/TUNA, which is associated with brain development in
zebraﬁsh, mouse, and human [35,36], as well as X-inactive
speciﬁc transcript (Xist), which is involved in X-inactivation
[37]. It is possible that RNA molecules need less sequence
conservation to retain their function compared to proteins.
Conversely, there is high sequence conservation of lncRNA
promoters, which is even higher than that of protein-coding
gene promoters [29], suggesting that regulation of lncRNA
expression is important.
Many lncRNAs possess features reminiscent of protein-
coding genes, such as 50 cap and alternative splicing [32].
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44 Genomics Proteomics Bioinformatics 14 (2016) 42–54In fact, many lncRNA genes have two or more exons [32] and
about 60% of lncRNAs have polyA+ tails [38] (Figure 1).
Additionally, while there are long intergenic RNAs (lincR-
NAs) [39] including eRNAs from gene-distal enhancers [40],
the majority of lncRNA genes are located within 10 kb of
protein-coding genes [41] and many lncRNAs are antisense
to coding genes or intronic [42].
In line with a wide range of functions that lncRNAs are
involved in, lncRNAs can be found in many tissues, although
the brain and central nervous system appear to have the high-
est diversity of expressed lncRNAs [43]. Also, lncRNAs can be
found in different cellular compartments including both the
cytoplasm and nucleus to which they seem to predominantly
localize [32]. lncRNAs have been generally thought to be
unstable due to their low expression levels and the existence
of known classes of unstable transcripts such as the promoter
upstream transcripts (PROMPTs) [44]. Interestingly, a recent
study indicates that only a minority (240 out of 823 lncRNAs;
29%) of lncRNAs are unstable with half-lives less than 2 h,
while 51 (6%) were extremely stable with half-lives of over
12 h [45].
Acting mechanisms of lncRNAs
In cancer, lncRNAs work through multiple mechanisms such
as chromatin remodeling, chromatin interactions, ceRNAs,
and natural antisense transcripts (NATs) (Figure 2). lncRNAs
can interface with chromatin remodeling machinery in several
ways, including acting as signal lncRNAs or scaffold
lncRNAs. Recently, another mechanism of action by which
lncRNAs function to regulate transcription has been posited.
This involves the production of lncRNAs from enhancer
regions in the genome (eRNAs), which function to stabilize
as well as maintain chromatin loops [40,46–48]. Chromatinlooping enables distally-located enhancers (with some located
several hundred kilobases away) to interact with their target
gene promoters [49–51]. In addition, several studies aimed
at elucidating the biological functions of miRNAs have pre-
viously used artiﬁcial miRNA sponges that compete with
native targets for interaction with the miRNAs of interest
[52–54]. Similarly, studies have also demonstrated that some
lncRNAs modulate transcription by sequestering regulatory
factors, including transcription factors and catalytic proteins
or subunits of larger chromatin-modiﬁcation complexes, as
well as miRNAs [22]. They are known as ceRNAs [55–57].
Transcribed from the opposite DNA strand in relative to
the sense transcripts, NATs overlap with their sense tran-
scripts [58] and are thought to regulate the expression of
the sense transcripts as well. We will discuss examples of
these mechanisms in the next sections. Nonetheless, it should
be noted that the mechanisms described here are not exhaus-
tive, and future work is likely to provide new insights in this
fast-moving ﬁeld.
lncRNAs in chromatin remodeling
lncRNAs can act through chromatin remodeling to achieve
transcriptional regulation. One example is the potassium
voltage-gated channel subfamily KT member 1 opposite
strand/antisense transcript 1 (KCNQ1OT1), which is upregu-
lated in colon cancer [59]. KCNQ1OT1 acts as a signal
lncRNA by recruiting G9a histone methyltransferases and
polycomb repressive complex 2 (PRC2) [21], which mediate
the gene-silencing-associated marks, i.e., dimethylation of
lysine 9 (H3K9me2) and lysine 27 on histone 3 (H3K27me3)
[60]. Through chromatin remodeling, KCNQ1OT1 induces
transcriptional silencing of genes, which may occur in cis (for
targets close by) or in trans (for distal targets).
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ncRNA in the INK4 locus, works as a scaffold in mediating
transcriptional silencing of the INK4b-ARF-INK4a locus by
recruiting and interacting with PRC1 and PRC2 [24,25].
PRC2 recruited to this gene locus then mediates the
spread of the methylation marks that are distinct for
transcriptionally-silent genes. Several lncRNAs have been
demonstrated to interact with chromosome-modiﬁcation com-
plexes and direct them to speciﬁc target genes. These guide
lncRNAs are essential for the proper localization of the
chromosome-modiﬁcation complexes including PRC2 and
subsequent repression of gene expression as demonstrated by
the lncRNA fetal-lethal non-coding developmental regulatory
RNA (FENDRR), which serves to bring PRC2 in close prox-
imity to the promoters of genes associated with the formation
and differentiation of the lateral mesoderm lineage, such as
forkhead box F1 (FOXF1) and paired-like homeodomain2
(PITX2) genes [26]. We hypothesize that other guide lncRNAs
may also function to regulate transcription by targeting other
chromatin-modiﬁcation complexes, in addition to PRC2, to
their target genes.
Finally, the HOX transcript antisense RNA (HOTAIR)
lncRNA functions cooperatively with PRC2 in mediating the
repression of the homeobox D cluster (HOXD) locus through
spreading H3K27me3 marks, which are associated with gene
silencing [61]. HOTAIR forms multiple double stem-loop
structures that bind to lysine-speciﬁc demethylase 1 (LSD1)
and PRC2 histone-modiﬁcation complexes [12]. Other
lncRNAs also operate in a similar manner, with as much as
20% of lncRNAs known to associate with PRC2 [62]. For
example, the lncRNA TUG1 is associated with PRC2, and
depletion of TUG1 expression in the developing mouse eye
leads to the blockage of retinal development [62]. While
PRC2 has been found to interact with many lncRNAs, other
chromatin remodelers have been implicated and it is likely that
more interactions with other chromatin remodelers remain to
be discovered. Moreover, given that cancers are associated
with aberrant levels of PRC2, H3K27me3, and mutated
enhancer of zeste homolog 2 (EZH2), which is a component
of the PRC2 complex [63], we hypothesize that lncRNA-
based mechanisms provide an explanation as to how these
alterations in PRC2 levels can give rise to cancer (Table 1).
Taken together, it is becoming increasingly clear that certain
lncRNAs can associate with chromatin-modiﬁcation com-
plexes to carry out cellular functions.lncRNAs in chromatin looping in cancers
Another mechanism of action by which lncRNAs function to
regulate transcription is via enhancer lncRNAs (eRNAs) asso-
ciated with chromatin loops. To study chromatin looping,
techniques including chromosome conformation capture (3C)
[64] and ﬂuorescence in situ hybridization (FISH) [65], have
been employed. More recent technical developments have
focused on higher-throughput analyses and these include circu-
lar chromosome conformation capture (4C) [66,67], chromo-
some conformation capture carbon copy (5C) [68], combined
3C-ChIP-cloning (6C) [69], chromatin interaction analysis with
paired-end tag sequencing (ChIA-PET) [70], and Hi-C [71].
Using ChIA-PET, a correlation is revealed between expression
level of elncRNAs and estrogen receptor a (ERa)-associated
chromatin interactions [72]. The experimental downregulation
of these eRNAs leads to a loss of chromatin loops and a
corresponding change in expression of the genes targeted by
ERa [46].
In addition, a relationship is found between the levels of
eRNAs produced by upstream enhancers of the prostate-
speciﬁc antigen (PSA) gene and the actual levels of PSA gene
expression, suggesting a possible link between eRNAs and
chromatin interactions [73]. Melo et al. show the existence of
enhancer regions that bind the transcription factor p53. These
enhancer regions produce RNAs and display chromatin inter-
actions with multiple neighboring genes. Ablation of these
eRNAs leads to reduced transcription at neighboring genes
and reduced p53-dependent cell cycle arrest [74]. More
recently, a role for Integrator in the biogenesis of eRNAs is
demonstrated [75]. Integrator is a complex associated with
RNA polymerase II (RNAPII), and possesses RNA endonu-
clease activity, which is required for 30 end processing of
non-polyadenylated nuclear RNA genes [76]. These studies
show that depletion of Integrator leads to a decrease in the
induction of eRNAs, which is accompanied by the loss of
enhancer-promoter chromatin looping [75].
One of the best examples of lncRNAs that regulate chro-
matin interactions is the HOXA transcript at the distal tip
(HOTTIP). HOTTIP is a lncRNA shown to regulate
chromatin interactions in the HOX cluster, from which it is
produced. HOTTIP is necessary to coordinate activation of
HOX genes, through binding WD repeat-containing protein
5 (WDR5), an adaptor protein [77]. WDR5 interacts with
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recognition and genomic targeting. The MLL complexes cat-
alyze H3K4 methylation, which is a mark of actively tran-
scribed genes [77]. HOTTIP is necessary for the maintenance
of a speciﬁc pattern of WDR5/MLL complexes across the
HOXA locus to facilitate gene transcription [77].
Additionally, there is cross-talk between the different mech-
anisms: a novel RNA chromosome conformation capture
(R3C) strategy demonstrated that KCNQ1OT1, which regu-
lates genes in the KCNQ1 imprinting region, is involved in
imprinting-associated chromatin interactions [78]. EZH2,
which catalyzes the deposition of gene silencing-associated
H3K27me3 marks, is recruited by the KCNQ1OT1 [78]. Deple-
tion of KCNQ1OT1 leads to depletion of the loop and loss of
imprinting [78]. These examples all demonstrate a role for
eRNA-associated chromatin interactions in transcriptional
suppression, enhancement, and coordination of gene expres-
sion, as well as other functions such as imprinting. A hypoth-
esized model of action is that eRNAs may help to tether
different genomic regions together, recruiting factors such as
PRC2 and other proteins at the 50 end, while remaining teth-
ered to the location of production [79] (Figure 3). Other factors
might help to bring together other DNA regions, or the length
of the eRNA might enable it to tether and guide other DNA
regions together, thus forming a chromatin interaction. Other
factors may bind to the chromatin directly or indirectly
through the bound proteins, stabilizing and maintaining the
chromatin even after the RNA may have been degraded. For
example, cohesin has been shown to play such a role in the case
of ERa-associated RNAs [46]. Adding support to this idea is
the ﬁnding that transcriptional repressor CCCTC-binding fac-
tor (CTCF), which is involved in chromatin interactions, can
bind to ncRNAs. For example, the steroid receptor RNA acti-
vator (SRA) binds to CTCF and enhances its functioning [80].lncRNAs as ceRNAs in cancers
The lncRNA HULC is highly upregulated in hepatocellular
carcinoma (HCC) [81]. There are multiple miR-372-binding
sites present in HULC, and the overexpression of HULC can
reduce miR-372 expression. This leads to reduced translational
repression of its target transcript PRKACB, thereby inducing
the phosphorylation of the cAMP-responsive element (CRE)-
binding protein (CREB) [81]. On the other hand, papillary thy-
roid carcinoma susceptibility candidate 3 (PTCSC3) is highly
downregulated in thyroid cancers and its overexpression leads
to reduced expression of oncogenic miR-574-5p, resulting in
growth inhibition, cell-cycle arrest, and increased apoptosis
[82]. Studies identifying additional molecular targets of decoy
lncRNAs will add to our understanding of diseases while pre-
senting possible therapeutic interventions for which drugs may
be designed.
lncRNAs as NATs
NATs are surprisingly common in the mammalian genome—
over 20% of human transcripts form sense–antisense pairs
[83]. A later estimate in mice based on large RNA-seq datasets
shows that up to 72% of genes may have transcription-related
activity on the opposite strand [58]. NATs can be producedagainst both protein-coding and non-coding genes [58] and
some NATs are protein-coding genes while others are
lncRNAs [58]. In addition, the genomic organization of NAT-
sin relative to their sense transcripts varies with different con-
ﬁgurations. One common conﬁguration, called ‘‘divergent”, is
that the promoter generates bidirectional transcription [58,84].
Another common conﬁguration, called ‘‘convergent”, arises
whereby the NAT starts from a different promoter, and tran-
scribes a region on the opposite strand from the protein-coding
transcript [58]. For example, the NAT could start from the 30
end of the sense transcript and transcribe toward its 50 end [58].
NATs exert varied inﬂuence on their sense transcripts,
either suppression or activation. The expression levels of
sense/antisense pairs are generally concordant, but reciprocal
expression is also observed [58]. NATs can work through a
variety of mechanisms. Other than employing mechanisms
similar to other lncRNAs such as by scaffolding proteins,
NATs that overlap with sense transcripts can work through
a particular mechanism, that is, transcriptional collision.
RNAPII complexes transcribing on opposite DNA strands
cannot bypass each other [85]. Head-to-head collision results
in stalling of RNAPII and subsequent removal of collided
RNAPII by ubiquitin-directed proteolysis [85]. Therefore, con-
vergent sense and antisense transcripts could lead to sense
strand suppression.
One example of a NAT in cancer is WD40-encoding RNA
antisense to p53 (Wrap53) [86]. As a NAT of the important
oncogene TP53, Wrap53 can induce TP53 expression by tar-
geting the 50 untranslated region of the TP53 mRNA [86].
Blocking this interaction between the Wrap53 lncRNA and
TP53 mRNA reduces basal levels of TP53 and prevents induc-
tion of TP53 after DNA damage [86].Wrap53 is overexpressed
Fang Y and Fullwood MJ /Long Non-coding RNAs in Cancer 47in cancer cell lines; interestingly, overexpression of Wrap53
results in cellular transformation while ablation leads to apop-
tosis [87]. Additionally, Wrap53 overexpression is correlated
with poor prognosis in head and neck squamous cell carci-
noma [87]. Taken together, Wrap53 is an oncogenic lncRNA
that regulates TP53 expression.
lncRNA networks and cross-talk in cancer
An interesting aspect of lncRNAs is that there can be cross-
talk between different mechanisms, leading to the formation
of complex networks, particularly in cancer. For example,
the transcription factor p53 regulates many genes [88], includ-
ing lncRNAs such as lncRNA-p21, PANDA, H19, and
loc285184, which serve as effectors of p53 by leading to
p53-associated cellular functions such as cell cycle arrest and
apoptosis [89]. p53 is self-regulated not only by well-known
regulators such as MDM2, an E3 ubiquitin ligase, but also
by lncRNAs MALAT1, and MEG3, as well as the TP53NAT-
Wrap53 as discussed in the previous section [89]. MALAT1 is
upregulated in several cancers [90] and may be used to predict
survival and metastasis in non-small cell lung cancer [91]. And
MALAT1 is expressed in a cell cycle-dependent manner and is
required for G1/S and mitotic progression [92]. Paradoxically,
depletion ofMALAT1 leads to TP53 activation [92]. However,
the cells show reduced oncogenic transcription factor B-MYB,
leading to increased cellular proliferation via B-MYB [92]. For
more details on these lncRNAs, readers are referred to the
excellent review by Zhang and colleagues [89]. Interestingly,
c-Myc, another important cancer-associated transcription fac-
tor, has a similar network [93]. It remains an open question
whether other cancer-associated transcription factors possess
a similar network consisting of lncRNAs that lead to altered
cellular functions and ultimately cancer. Given that transcrip-
tion factors are generally considered difﬁcult to target by small
molecule inhibitors due to the intrinsically disordered natureTable 2 Examples of key technologies and tools for identifying and an
Technique Purpose
RNA-seq Used to characterize and annotate RN
abundance and exonic structure of the R
of alternative splicing
Custom arrays Custom lncRNA microarrays used to s
diﬀerent samples; custom tiling microa
speciﬁc regions of the genome; custom
capture
RIP-Seq Used to characterize RNAs that bind t
ChIRP-Seq Used to characterize DNA or RNA or
RNA-FISH Used to visualize the location of the ln
RNA-3C Used to investigate associations betwee
organization
Structure-Seq Used to infer the secondary structure o
determination methods available, such
CRISPR Used to engineer knock-outs or knock
loci of lncRNAs
ASO Used to perturb particular lncRNAs an
DNAs, or RNAs
Note: RIP-Seq, RNA immunoprecipitation-Seq; ChIRP-Seq, chromatin iso
hybridization; RNA-3C, RNA-chromosome conformation capture; SHAP
sequencing; PARS, parallel analysis of RNA structure; FRAG-Seq, fragm
palindromic repeat; ASO, antisense oligonucleotide.of their binding sites (meaning they lack stable secondary
and/or tertiary structure under physiological conditions
in vitro) and their binding promiscuity [94], lncRNAs that reg-
ulate the transcription factors may open up new avenues for
targeting cancers with aberrant transcription factor signaling.Approaches for the identification and annotation of
lncRNAs
In general, the expression levels of lncRNAs are low in abun-
dance and lncRNAs are often not polyA-tailed, posing several
challenges for their identiﬁcation and analysis because previ-
ous methods of microarray and mRNA-seq rely on polyA+
isolation and tend to favor the detection of transcripts that
are abundant in expression. In spite of these challenges, a num-
ber of effective methods have been developed for lncRNA
identiﬁcation and annotation (Table 2). Today, RNA-seq is
one of the most common methods for identifying novel
lncRNAs, because of the dropping sequencing costs and
the single-nucleotide resolution nature of RNA-seq [95].
RNA-seq involves converting RNA into cDNA, followed by
fragmentation, and ultra-high-throughput sequencing by
methods such as Illumina HiSeq. As lncRNAs have low
expression levels, high sequencing depths of 100–150 million
reads or more are needed to discover these rare lncRNAs
[96]. In addition, strand-speciﬁc sequencing methods are also
needed to distinguish antisense lncRNAs from sense
transcripts and cDNA conversion must be performed using
random hexamers as opposed to oligo-dT methods [96].
RNA-seq experiments to detect lncRNAs have to be per-
formed through rRNA-depletion to enrich for mRNAs and
lncRNAs or by sequencing both polyA+ and polyA frac-
tions [96]. Owing to the high sequencing depth, RNA-seq
becomes expensive when investigating some of the rarest
lncRNAs. Hence researchers have also turned to customnotating lncRNAs
Refs.
As, including lncRNAs. It provides the
NAs, allowing for better understanding
[95]
creen through many lncRNAs in many
rrays used to identify lncRNAs in
microarrays used to perform sequence
[98]
o a particular protein of interest [101]
proteins from chromatin complexes [46,102]
cRNAs in diﬀerent cellular organelles [103]
n lncRNAs and 3-D genome [78]
f RNA with several structure
as SHAPE-Seq, PARS, and FRAG-Seq
[104–107]
-ins or other constructs at the genomic [108,109]
d their interactions with other proteins, [121–123]
lation by RNA puriﬁcation-Seq; RNA-FISH, RNA-ﬂuorescence in situ
E-Seq, selective 20-hydroxyl acylation analyzed by primer extension
entation sequencing; CRISPR, clustered regularly interspaced short
48 Genomics Proteomics Bioinformatics 14 (2016) 42–54lncRNA microarrays to screen through many lncRNAs in
many different samples [97], as well as custom tiling microar-
rays to identify lncRNAs in speciﬁc regions of the genome
[61]. Other than that, microarray capture followed by sequenc-
ing is also used for quantitative gene proﬁling and annotation
of speciﬁc lncRNAs [98].
Several new sequencing methods are becoming available,
such as Paciﬁc Biosciences (PacBio) sequencing, which features
extremely long (on the order of kilobases) reads [99,100]. Pac-
Bio sequencing allows for read-through of complete gene
sequences, facilitating the understanding of alternative splic-
ing. While this method is currently only cost-effective for small
genomes such as bacteria, in the near-future, it will probably
be applicable to analysis of human samples.
There is a battery of experimental methods for annotating
lncRNAs. RNA immunoprecipitation (RIP)-Seq involves
sequencing RNAs that are associated with a particular
RNA-binding protein of interest with immunoprecipitation
[101]. A related method, chromatin isolation by RNA puriﬁca-
tion (ChIRP)-Seq involves the design of multiple biotin-tagged
oligonucleotide probes that recognize a particular RNA
[46,102]. Cross-linked chromatin complexes with RNA of
interest are then isolated using streptavidin magnetic beads
recognizing the biotin tag [46,102]. DNA, RNA, and protein
can be isolated from these complexes and subjected to sequenc-
ing or mass spectrometry for identiﬁcation [46,102]. Another
method, RNA-FISH, involves designing ﬂuorescent probes
to RNA and performing the hybridization in cells followed
by microscopic imaging. It is used to visualize the location of
the lncRNAs in different cellular organelles and investigate
how lncRNA localization is altered in response to different
stimuli [103]. In addition, RNA-3C involves double-stranded
cDNA synthesis using biotinylated oligonucleotides to obtain
chromatin complexes with biotinylated cDNA, followed by
digestion and proximity ligation, generating DNA-cDNA con-
structs. These constructs can then be pulled down using the
biotin group and analyzed by PCR. RNA-3C has been used
to investigate associations between lncRNAs and 3-D genome
organization [78].
In addition, there are a variety of sequencing methods for
analyzing the secondary structure of RNA. These include
selective 20-hydroxyl acylation analyzed by primer extension
sequencing (SHAPE-Seq), whereby RNA is isolated, bar-
coded, and folded in vitro [104]. A SHAPE reagent, 1M7, is
added to the isolated, barcoded, and folded RNA, which
blocks the reverse transcriptase reaction whereby the 1M7 is
included in the RNA, and hence leads to a series of truncated
products to be sequenced, allowing for reconstruction of the
original structure [104]. A similar method, parallel analysis
of RNA structure (PARS) involves digestion of RNAs using
RNAses speciﬁc for double-stranded and single-stranded
RNAs. The fragments are then reversely transcribed and com-
pared with each other, allowing for deduction of RNA struc-
tures in vivo [105,106]. A third method, fragmentation
sequencing (FRAG-Seq), is similar to PARS except that it uses
P1 nuclease instead of RNAses [107].
Perturbing lncRNA expression levels can be achieved in
different ways, including clustered regularly interspaced short
palindromic repeat (CRISPR) genomic editing of lncRNA
genes [108,109]. In addition, new antisense oligonucleotide
(ASO) approaches can be applied to perturb both cytoplas-
mic and nuclear lncRNAs, which will be discussed in moredetails in the next section. CRISPR genomic editing comes
from the immune defenses of bacteria and archaea, which
use short RNA to degrade invading nucleic acids [110,111].
Being one component of the CRISPR immune defense sys-
tem, Cas9 effector nuclease is the ﬁrst known nuclease that
is capable of binding to speciﬁc short RNA and thereby
directing cleavage at complementary genomic loci [110].
CRISPR/Cas9 represents a giant leap forward in terms of
ease of use and efﬁciency in comparison with traditional
methods for excising DNA such as homologous recombina-
tion and zinc ﬁnger nucleases (ZFNs) [110]. This method
has since been widely adopted by many labs around the
world, in a wide range of different cell types and organisms
[110]. CRISPR editing can also be used to excise lncRNAs
for functional studies. In addition, CRISPR can be modiﬁed
for other purposes such as upregulating gene expression by
combining a Cas9 unable to cleave nucleic acids with
transcription activators such as VP64 activator domains
[110,112,113]. This system could be used to upregulate
lncRNA expression levels to understand their functions.
There are several databases available for lncRNA research
(Table 3). ENCODE [28], FANTOM [114], and TCGA [115]
have all embarked on massive RNA-seq efforts in different
tissues including patient samples, which have yielded an
unprecedented collection of lncRNAs. In addition, several
groups have developed curated lists of lncRNAs by mining
the existing literature and by predictions. For example,
lncRNome [116] can serve as a general resource, while
LncRNA Disease [117] presents lncRNA–disease associations.
Other groups have also developed bioinformatics tools to infer
functions of lncRNAs. These include looking for co-expressed
genes and lncRNAs as featured in the lncRNAtor database
[118], looking at functional similarity patterns (motifs) and
predicting RNA structures as featured in LNCipedia and
lncRNome [116,119], and integrating epigenomic information
as featured in lncRNome [116]. For a detailed discussion and
comparison of lncRNA databases, we refer readers to the arti-
cle by Fritah and colleagues [120].ASOs for modulation of lncRNA
The importance of lncRNAs in health and diseases (Table 1)
indicates a need to ﬁnd methods for modulating lncRNAs.
To do this, ASOs are used (Figure 4), which are short DNA
sequences and complementary to an RNA of interest. The
oligonucleotide works by hybridizing to the RNA, which then
blocks the action of the RNA. While unmodiﬁed oligonu-
cleotides are available, certain chemical modiﬁcations such as
20-O-(2-methoxy) ethyl oligonucleotides increase the lifespan
of the oligonucleotide in the complex milieu of nucleases
within the cell, and reduce degradation products, which may
also have effects on the cells [121]. Two ASOs have been
approved as drugs by the Food and Drug Administration
(FDA) of the United States: fomivirsen, which is used to treat
cytomegalovirus retinitis [122], and mipomersen, which is used
to treat homozygous familial hypercholesterolemia [123].
ASOs can enter the nucleus and knock down nuclear lncRNAs
[124], enabling all classes of lncRNAs to be explored. In con-
trast, siRNA and shRNA are not effective in targeting nuclear
lncRNAs because the RNAi machinery is located in the
cytoplasm.
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Figure 4 Targeting lncRNAs for therapeutic applications
NAT, natural antisense transcript; PRC2, polycomb repressive complex 2; ASO, antisense oligonucleotide; eRNA, enhancer RNA.
Table 3 Key databases of lncRNAs
Database Description Web link Ref.
Databases with RNA-seq and other primary datasets
ENCODE Produced many RNA-seq and complementary datasets for a certain set
of human cell lines
https://genome.ucsc.edu/ENCODE/ [28]
FANTOM Produced many RNA-seq and complementary datasets from mice http://fantom.gsc.riken.jp/ [114]
TCGA Contains lncRNAs from primary patient tumors http://cancergenome.nih.gov/ [115]
Curated lists of lncRNAs
lncRNome A curated list of >17,000 annotated lncRNAs with information on
chromosomal locations, biological functions, diseases associations, and
the types of the lncRNAs. Datasets on protein–lncRNA interactions
and genomic variations in lncRNA loci are also accessible from this
database
http://genome.igib.res.in/lncRNome/ [116]
LNCipedia An integrated database with a curated list of 111,685 annotated
lncRNAs obtained from diﬀerent sources. This database provides
transcript and structure information on the lncRNAs as well as
statistics for secondary structure information, protein coding potential,
and microRNA binding sites
http://www.lncipedia.org/ [119]
LncRNADisease A curated list of >1000 lncRNA–disease associated data from 500
publications, as well as predictions of novel lncRNA–disease
associations of 1564 human lncRNAs
http://www.cuilab.cn/lncrnadisease [117]
Annotators
LncRNAtor Co-expression between mRNAs and lncRNAs in various tissues http://lncrnator.ewha.ac.kr/index.htm [118]
Fang Y and Fullwood MJ /Long Non-coding RNAs in Cancer 49A major interest for antisense therapy is to upregulate gene
expression. Several lncRNAs work as NATs to genes of
therapeutic interest. Classic small molecule drugs work by
inhibiting gene expression; therefore genes that need to be
upregulated have been almost undruggable, although enzyme
replacement therapy has been used as a strategy, such as
lysosomal enzymes in the case of lysosomal storage diseases
[125]. Antisense targeting of natural antisense lncRNAs, or
‘‘antagoNATs”, provides a very speciﬁc way for geneupregulation [126,127]. Taken together, ASOs constitute a
very promising tool that can be used to translate basic discov-
eries about lncRNAs to the clinic. For instance, Opko-Curna
is a company taking forward this technology into the clinic
[126].
Similarly, company RaNa Therapeutics aims to upregulate
gene expression, but using a different approach [128]. Using
RIP-Seq, thousands of lncRNAs were found to interact with
PRC2, which represses transcription of the genes targeted by
50 Genomics Proteomics Bioinformatics 14 (2016) 42–54lncRNAs [101]. Notably, speciﬁc PRC2-lncRNA interactions
can be disrupted using locked nucleic acids, resulting in upreg-
ulation of the target genes [129]. Locked nucleic acids are
RNA derivatives similar in principle to ASOs [130]. Therefore,
the company is keen to de-repress the expression of genes of
interest by using locked nucleic acids against speciﬁc lncRNAs
that interact with PRC2.
Given that lncRNAs have been found to act in other path-
ways, such as eRNAs, they have additional potential in terms
of therapeutic mechanisms that can be targeted by ASOs. For
example, transcription factors, chromatin modulators, and
chromatin interactions are difﬁcult pathways to target, as these
factors are in the nucleus, which is difﬁcult for small molecule
inhibitors to enter. ASOs against lncRNAs, which interact
with factors that can enter the nucleus, might offer a feasible
mechanism for future targeting of these important pathways.
Future directions
A major challenge to work on lncRNAs is that despite their
importance, the molecular mechanisms underlying their func-
tions are not yet fully understood. Further insight into the bio-
logical signiﬁcance and functioning of lncRNAs will require
additional studies to be conducted, which may lead to the dis-
covery of yet more mechanisms of action. Several functions are
just starting to be appreciated, such as roles in alternative
splicing. For example, MALAT1 controls alternative splicing
by regulating the phosphorylation and distribution of serine/
arginine splicing factors in nuclear speckle domains [131]. It
is likely that other lncRNAs will be found that regulate alter-
native splicing through other mechanisms. Moreover, this
review did not cover novel mechanisms and forms of lncRNAs
such as circular RNA [132]. These novel forms will need to be
explored in more details, and their possible relevance to cancer
pathways will also need to be examined.
Further confounding factors in our understanding of
lncRNAs is that lncRNAs can have more than one mecha-
nisms of action to confer transcriptional activation or repres-
sion of their target genes. For example, KCNQ1OT1 can
function as both a signal lncRNA [133] and a guide lncRNA
[21]. In addition, HOTAIR acts via at least three mechanisms
namely signal, decoy, and guide [134]. These studies suggest
that for many lncRNAs, even lncRNAs that have been charac-
terized, new mechanisms may yet be uncovered.
Moreover, it is unclear whether there exists correlation
between particular functioning mechanisms of lncRNAs and
their roles in cancer. For example, XIST is a lncRNA with a
well-established role in dosage compensation in the fruitﬂy
[135] and mammals [136]. XIST lncRNA is exclusively pro-
duced by the XIST gene located on the inactive X-
chromosome [137]. Notably, such inactivation is mediated by
the ability of XIST to recruit chromatin-modiﬁcation com-
plexes [37]. At the same time, aberrant expression of XIST
has been linked to a variety of cancers [138]. One mechanism
that XIST may function through is as a miRNA sponge for
miR-152 [11]. This raises interesting questions such as whether
this is the only mechanism of action for XIST in cancer? Does
the role of XIST in dosage compensation also have anything to
do with its role in cancer?
Another direction is to understand how different lncRNAs
cross talk with each other, and how aberrant cross-talk may beregulated in cancer. Laying the ground for further work are
new technologies, for example new sequencing methods that
can directly sequence RNA and RNA modiﬁcations without
the need for reverse transcription. In addition, miniaturization
of sequencing devices could enable the development of hand-
held RNA-seq devices that rapidly analyze miRNAs and
lncRNAs of interest in patient blood samples or biopsies,
quickly providing insights into RNA biology that may be dys-
regulated in individual patients, thereby helping pave the way
to an era of precise, personalized evaluation of patient health
and disease.
In conclusion, enhanced understanding of lncRNAs in can-
cer will shed light into disease etiology and will help guide
future diagnosis as well as therapeutic options. In future, with
the potential therapeutic options for modulating lncRNAs in
the form of ASOs as well as other technologies that may arise,
lncRNA-based therapies could become an important health-
care strategy for consideration.Competing interests
MJF is a co-inventor on 2 patents related to chromatin
interactions. There are no other conﬂicts of interest to be
declared.Acknowledgments
We would like to thank members of the Fullwoodlab for help-
ful suggestions and comments. This research is supported by
the National Research Foundation (NRF) of Singapore
through an NRF fellowship awarded to MJF (Grant No.
NRFF2012-054), NTU startup funds, and Yale-NUS start-
up funds awarded to MJF. In addition, this research is sup-
ported by funds given to the Cancer Science Institute (CSI),
National University of Singapore (NUS), by the NRF and
the Ministry of Education - Singapore under the Research
Center of Excellence funding. This research is also supported
by the RNA Biology Center at the CSI, NUS, as part of the
funding under the Tier 3 grants of the Ministry of Education,
Singapore.
References
[1] Berretta J, Morillon A. Pervasive transcription constitutes a new
level of eukaryotic genome regulation. EMBO Rep
2009;10:973–82.
[2] Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T,
Mortazavi A, et al. Landscape of transcription in human cells.
Nature 2012;489:101–8.
[3] Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcrip-
tion of the human genome produces thousands of previously
unidentiﬁed long intergenic noncoding RNAs. PLoS Genet
2013;9:e1003569.
[4] Bernstein BE, Birney E, Dunham I, Green ED, Gunter C,
Snyder M. An integrated encyclopedia of DNA elements in the
human genome. Nature 2012;489:57–74.
[5] Bushati N, Cohen SM. MicroRNA functions. Annu Rev Cell
Dev Biol 2007;23:175–205.
[6] Esteller M. Non-coding RNAs in human disease. Nat Rev Genet
2011;12:861–74.
[7] He L, Hannon GJ. MicroRNAs: small RNAs with a big role in
gene regulation. Nat Rev Genet 2004;5:522–31.
Fang Y and Fullwood MJ /Long Non-coding RNAs in Cancer 51[8] Gutschner T, Diederichs S. The hallmarks of cancer: a long non-
coding RNA point of view. RNA Biol 2012;9:703–19.
[9] Ellis BC, Molloy PL, Graham LD. CRNDE: a long non-coding
RNA involved in cancer, neurobiology, and development. Front
Genet 2012;3:270.
[10] Wang P, Ren Z, Sun P. Overexpression of the long non-coding
RNA MEG3 impairs in vitro glioma cell proliferation. J Cell
Biochem 2012;113:1868–74.
[11] Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, et al. Knockdown of
long non-coding RNA XIST exerts tumor-suppressive functions
in human glioblastoma stem cells by up-regulating miR-152.
Cancer Lett 2015;359:75–86.
[12] Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ,
et al. Long non-coding RNA HOTAIR reprograms chromatin
state to promote cancer metastasis. Nature 2010;464:1071–6.
[13] Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S,
Sudo T, et al. Long noncoding RNA HOTAIR regulates
polycomb–dependent chromatin modiﬁcation and is associated
with poor prognosis in colorectal cancers. Cancer Res
2011;71:6320–6.
[14] Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F,
et al. Overexpression of long non-coding RNA HOTAIR
predicts tumor recurrence in hepatocellular carcinoma
patients following liver transplantation. Ann Surg Oncol
2011;18:1243–50.
[15] Quagliata L, Matter M, Piscuoglio S, Makowska Z, Heim M,
Tornillo L, et al. Hoxa13 and Hottip expression levels predict
patients’ survival and metastasis formation in hepatocellular
carcinoma. J Hepatol 2013;58:S39–40.
[16] Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI,
Scadden DT, et al. Xist RNA is a potent suppressor of
hematologic cancer in mice. Cell 2013;152:727–42.
[17] Brunner AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R,
et al. Transcriptional proﬁling of long non-coding RNAs and
novel transcribed regions across a diverse panel of archived
human cancers. Genome Biol 2012;13:R75.
[18] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs:
insights into functions. Nat Rev Genet 2009;10:155–9.
[19] Li XL, Wu ZQ, Fu XB, Han WD. LncRNAs: insights into their
function and mechanics in underlying disorders. Mutat Res Rev
Mut Res 2014;762:1–21.
[20] Moran VA, Perera RJ, Khalil AM. Emerging functional and
mechanistic paradigms of mammalian long non-coding RNAs.
Nucleic Acids Res 2012;40:6391–400.
[21] Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L,
Komorowski J, et al. Kcnq1ot1 antisense noncoding RNA
mediates lineage-speciﬁc transcriptional silencing through chro-
matin-level regulation. Mol Cell 2008;32:232–46.
[22] Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The
imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell
2013;52:101–12.
[23] Yang L, Froberg JE, Lee JT. Long noncoding RNAs: fresh
perspectives into the RNA world. Trends Biochem Sci
2014;39:35–43.
[24] Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA,
polycomb, and the ghosts haunting INK4b-ARF-INK4a expres-
sion. Cancer Res 2011;71:5365–9.
[25] Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N,
Kitagawa M, et al. Long non-coding RNA ANRIL is required
for the PRC2 recruitment to and silencing of p15(INK4B) tumor
suppressor gene. Oncogene 2011;30:1956–62.
[26] Grote P, Wittler L, Hendrix D, Koch F, Wahrisch S, Beisaw A,
et al. The tissue-speciﬁc lncRNA Fendrr is an essential regulator
of heart and body wall development in the mouse. Dev Cell
2013;24:206–14.
[27] Ingolia NT, Lareau LF, Weissman JS. Ribosome proﬁling of
mouse embryonic stem cells reveals the complexity and dynamics
of mammalian proteomes. Cell 2011;147:789–802.[28] Consortium EP, Birney E, Stamatoyannopoulos JA, Dutta A,
Guigo R, Gingeras TR, et al. Identiﬁcation and analysis of
functional elements in 1% of the human genome by the
ENCODE pilot project. Nature 2007;447:799–816.
[29] Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC,
Maeda N, et al. The transcriptional landscape of the mammalian
genome. Science 2005;309:1559–63.
[30] Chooniedass-Kothari S, Emberley E, Hamedani MK, Troup S,
Wang X, Czosnek A, et al. The steroid receptor RNA activator is
the ﬁrst functional RNA encoding a protein. FEBS Lett
2004;566:43–7.
[31] Warden CD, Kim SH, Yi SV. Predicted functional RNAs within
coding regions constrain evolutionary rates of yeast proteins.
PLoS One 2008;3:e1559.
[32] Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner
H, et al. The GENCODE v7 catalog of human long noncoding
RNAs: analysis of their gene structure, evolution, and expres-
sion. Genome Res 2012;22:1775–89.
[33] Necsulea A, Soumillon M, Warnefors M, Liechti A, Daish T,
Zeller U, et al. The evolution of lncRNA repertoires and
expression patterns in tetrapods. Nature 2014;505:635–40.
[34] Kutter C, Watt S, Stefﬂova K, Wilson MD, Goncalves A,
Ponting CP, et al. Rapid turnover of long noncoding RNAs and
the evolution of gene expression. PLoS Genet 2012;8:e1002841.
[35] Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. Conserved
function of lincRNAs in vertebrate embryonic development
despite rapid sequence evolution. Cell 2011;147:1537–50.
[36] Lin N, Chang KY, Li Z, Gates K, Rana ZA, Dang J, et al. An
evolutionarily conserved long noncoding RNA TUNA controls
pluripotency and neural lineage commitment. Mol Cell
2014;53:1005–19.
[37] Brockdorff N, Ashworth A, Kay GF, McCabe VM, Norris DP,
Cooper PJ, et al. The product of the mouse Xist gene is a 15 kb
inactive X-speciﬁc transcript containing no conserved ORF and
located in the nucleus. Cell 1992;71:515–26.
[38] Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S,
et al. Transcriptional maps of 10 human chromosomes at 5-
nucleotide resolution. Science 2005;308:1149–54.
[39] Ulitsky I, Bartel DP. LincRNAs: genomics, evolution, and
mechanisms. Cell 2013;154:26–46.
[40] LamMT, Li W, Rosenfeld MG, Glass CK. Enhancer RNAs and
regulated transcriptional programs. Trends Biochem Sci
2014;39:170–82.
[41] Jia H, Osak M, Bogu GK, Stanton LW, Johnson R, Lipovich L.
Genome-wide computational identiﬁcation and manual annota-
tion of human long noncoding RNA genes. RNA
2010;16:1478–87.
[42] Rinn JL, Chang HY. Genome regulation by long noncoding
RNAs. Annu Rev Biochem 2012;81:145–66.
[43] Ravasi T, Suzuki H, Pang KC, Katayama S, Furuno M,
Okunishi R, et al. Experimental validation of the regulated
expression of large numbers of non-coding RNAs from the
mouse genome. Genome Res 2006;16:11–9.
[44] Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen
MS, Mapendano CK, et al. RNA exosome depletion reveals
transcription upstream of active human promoters. Science
2008;322:1851–4.
[45] Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini
E, Moscato P, et al. Genome-wide analysis of long noncoding
RNA stability. Genome Res 2012;22:885–98.
[46] Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, et al.
Functional roles of enhancer RNAs for oestrogen-dependent
transcriptional activation. Nature 2013;498:516–20.
[47] Orom UA, Shiekhattar R. Long noncoding RNAs usher in a
new era in the biology of enhancers. Cell 2013;154:1190–3.
[48] Ounzain S, Pedrazzini T. The promise of enhancer-associated
long noncoding RNAs in cardiac regeneration. Trends Cardio-
vasc Med 2015;25:592–602.
52 Genomics Proteomics Bioinformatics 14 (2016) 42–54[49] Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range
interaction landscape of gene promoters. Nature
2012;489:109–13.
[50] Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P,
et al. Extensive promoter-centered chromatin interactions
provide a topological basis for transcription regulation. Cell
2012;148:84–98.
[51] Visel A, Rubin EM, Pennacchio LA. Genomic views of distant-
acting enhancers. Nature 2009;461:199–205.
[52] Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M,
Zingale A, et al. Endogenous microRNA can be broadly
exploited to regulate transgene expression according to tissue,
lineage and differentiation state. Nat Biotechnol
2007;25:1457–67.
[53] Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P,
et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med
2007;13:613–8.
[54] Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: com-
petitive inhibitors of small RNAs in mammalian cells. Nat
Methods 2007;4:721–6.
[55] Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In
vivo identiﬁcation of tumor- suppressive PTEN ceRNAs in an
oncogenic BRAF-induced mouse model of melanoma. Cell
2011;147:382–95.
[56] Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al.
Coding-independent regulation of the tumor suppressor PTEN
by competing endogenous mRNAs. Cell 2011;147:344–57.
[57] Salmena L, Poliseno L, Tay Y, Kats L, Pandolﬁ PP. A ceRNA
hypothesis: the Rosetta Stone of a hidden RNA language? Cell
2011;146:353–8.
[58] Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M,
Nakamura M, et al. Antisense transcription in the mammalian
transcriptome. Science 2005;309:1564–6.
[59] Nakano S, Murakami K, Meguro M, Soejima H, Higashimoto
K, Urano T, et al. Expression proﬁle of LIT1/KCNQ1OT1 and
epigenetic status at the KvDMR1 in colorectal cancers. Cancer
Sci 2006;97:1147–54.
[60] Czermin B, Melﬁ R, McCabe D, Seitz V, Imhof A, Pirrotta V.
Drosophila enhancer of Zeste/ESC complexes have a histone H3
methyltransferase activity that marks chromosomal polycomb
sites. Cell 2002;111:185–96.
[61] Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann
SA, et al. Functional demarcation of active and silent chromatin
domains in human HOX loci by noncoding RNAs. Cell
2007;129:1311–23.
[62] Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea
Morales D, et al. Many human large intergenic noncoding RNAs
associate with chromatin-modifying complexes and affect gene
expression. Proc Natl Acad Sci U S A 2009;106:11667–72.
[63] Volkel P, Dupret B, Le Bourhis X, Angrand PO. Diverse
involvement of EZH2 in cancer epigenetics. Am J Transl Res
2015;7:175–93.
[64] Dekker J, Rippe K, Dekker M, Kleckner N. Capturing
chromosome conformation. Science 2002;295:1306–11.
[65] Cremer T, Cremer C. Chromosome territories, nuclear architec-
ture and gene regulation in mammalian cells. Nat Rev Genet
2001;2:292–301.
[66] Simonis M, Klous P, Splinter E, Moshkin Y, Willemsen R, de
Wit E, et al. Nuclear organization of active and inactive
chromatin domains uncovered by chromosome conformation
capture-on-chip (4C). Nat Genet 2006;38:1348–54.
[67] Zhao Z, Tavoosidana G, Sjolinder M, Gondor A, Mariano P,
Wang S, et al. Circular chromosome conformation capture (4C)
uncovers extensive networks of epigenetically regulated intra-
and interchromosomal interactions. Nat Genet 2006;38:1341–7.
[68] Dostie J, Richmond TA, Arnaout RA, Selzer RR, Lee WL,
Honan TA, et al. Chromosome Conformation Capture
Carbon Copy (5C): a massively parallel solution for mappinginteractions between genomic elements. Genome Res 2006;16:
1299–309.
[69] Tiwari VK, Cope L, McGarvey KM, Ohm JE, Baylin SB. A
novel 6C assay uncovers Polycomb-mediated higher order
chromatin conformations. Genome Res 2008;18:1171–9.
[70] Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB,
et al. An oestrogen-receptor-alpha-bound human chromatin
interactome. Nature 2009;462:58–64.
[71] Nagano T, Lubling Y, Stevens TJ, Schoenfelder S, Yaffe E,
Dean W, et al. Single-cell Hi-C reveals cell-to-cell variability in
chromosome structure. Nature 2013;502:59–64.
[72] Hah N, Murakami S, Nagari A, Danko CG, Kraus WL.
Enhancer transcripts mark active estrogen receptor binding sites.
Genome Res 2013;23:1210–23.
[73] Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, et al. Enhancer
RNAs participate in androgen receptor-driven looping that
selectively enhances gene activation. Proc Natl Acad Sci U S A
2014;111:7319–24.
[74] Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E,
Oude Vrielink JA, et al. ERNAs are required for p53-dependent
enhancer activity and gene transcription. Mol Cell
2013;49:524–35.
[75] Lai F, Gardini A, Zhang A, Shiekhattar R. Integrator mediates
the biogenesis of enhancer RNAs. Nature 2015;525:399–403.
[76] Baillat D, Hakimi MA, Naar AM, Shilatifard A, Cooch N,
Shiekhattar R. Integrator, a multiprotein mediator of small
nuclear RNA processing, associates with the C-terminal repeat
of RNA polymerase II. Cell 2005;123:265–76.
[77] Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R,
Chen Y, et al. A long noncoding RNA maintains active
chromatin domain to coordinate homeotic gene expression.
Nature 2011;472:120–4.
[78] Zhang H, Zeitz MJ, Wang H, Niu B, Ge S, Li W, et al. Long
noncoding RNA-mediated intrachromosomal interactions
promote imprinting at the Kcnq1 locus. J Cell Biol 2014;204:
61–75.
[79] Lee JT. Lessons from X-chromosome inactivation: long ncRNA
as guides and tethers to the epigenome. Genes Dev
2009;23:1831–42.
[80] Yao H, Brick K, Evrard Y, Xiao T, Camerini-Otero RD,
Felsenfeld G. Mediation of CTCF transcriptional insulation by
DEAD-box RNA-binding protein p68 and steroid receptor
RNA activator SRA. Genes Dev 2010;24:2543–55.
[81] Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-
regulates long non-coding RNA, HULC expression through
interaction with microRNA-372 in liver cancer. Nucleic Acids
Res 2010;38:5366–83.
[82] Fan M, Li XY, Jiang W, Huang Y, Li JD, Wang ZM. A long
non-coding RNA, PTCSC3, as a tumor suppressor and a target
of miRNAs in thyroid cancer cells. Exp Ther Med
2013;5:1143–6.
[83] Chen J, Sun M, Kent WJ, Huang X, Xie H, Wang W, et al. Over
20% of human transcripts might form sense-antisense pairs.
Nucleic Acids Res 2004;32:4812–20.
[84] Lepoivre C, Belhocine M, Bergon A, Griffon A, Yammine M,
Vanhille L, et al. Divergent transcription is associated with
promoters of transcriptional regulators. BMC Genomics
2013;14:914.
[85] Hobson DJ, Wei W, Steinmetz LM, Svejstrup JQ. RNA
polymerase II collision interrupts convergent transcription.
Mol Cell 2012;48:365–74.
[86] Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C,
Wiman KG, Farnebo M. Wrap53, a natural p53 antisense
transcript required for p53 induction upon DNA damage. Mol
Cell 2009;33:462–71.
[87] Mahmoudi S, Henriksson S, Farnebo L, Roberg K, Farnebo M.
WRAP53 promotes cancer cell survival and is a potential target
for cancer therapy. Cell Death Dis 2011;2:e114.
Fang Y and Fullwood MJ /Long Non-coding RNAs in Cancer 53[88] Riley T, Sontag E, Chen P, Levine A. Transcriptional control of
human p53-regulated genes. Nat Rev Mol Cell Biol
2008;9:402–12.
[89] Zhang A, Xu M, Mo YY. Role of the lncRNA-p53 regulatory
network in cancer. J Mol Cell Biol 2014;6:181–91.
[90] Gibb EA, Vucic EA, Enﬁeld KS, Stewart GL, Lonergan KM,
Kennett JY, et al. Human cancer long non-coding RNA
transcriptomes. PLoS One 2011;6:e25915.
[91] Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM,
et al. MALAT-1, a novel noncoding RNA, and thymosin beta4
predict metastasis and survival in early-stage non-small cell lung
cancer. Oncogene 2003;22:8031–41.
[92] Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X,
et al. Long noncoding RNA MALAT1 controls cell cycle
progression by regulating the expression of oncogenic transcrip-
tion factor B-MYB. PLoS Genet 2013;9:e1003368.
[93] Deng K, Guo X, Wang H, Xia J. The lncRNA-MYC regulatory
network in cancer. Tumour Biol 2014;35:9497–503.
[94] Dunker AK, Uversky VN. Drugs for ‘protein clouds’: targeting
intrinsically disordered transcription factors. Curr Opin Phar-
macol 2010;10:782–8.
[95] Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool
for transcriptomics. Nat Rev Genet 2009;10:57–63.
[96] Ilott NE, Ponting CP. Predicting long non-coding RNAs using
RNA sequencing. Methods 2013;63:50–9.
[97] Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS,
Maracaja-Coutinho V, et al. Long noncoding intronic RNAs are
differentially expressed in primary and metastatic pancreatic
cancer. Mol Cancer 2011;10:141.
[98] Clark MB, Mercer TR, Bussotti G, Leonardi T, Haynes KR,
Crawford J, et al. Quantitative gene proﬁling of long noncoding
RNAs with targeted RNA sequencing. Nat Methods
2015;12:339–42.
[99] Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, et al. An
integrated catalog of reference genes in the human gut micro-
biome. Nat Biotechnol 2014;32:834–41.
[100] Rhoads A, Au KF. PacBio sequencing and its applications.
Genomics Proteomics Bioinformatics 2015;13:278–89.
[101] Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K,
et al. Genome-wide identiﬁcation of polycomb-associated RNAs
by RIP-seq. Mol Cell 2010;40:939–53.
[102] Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic
maps of long noncoding RNA occupancy reveal principles of
RNA-chromatin interactions. Mol Cell 2011;44:667–78.
[103] Dunagin M, Cabili MN, Rinn J, Raj A. Visualization of lncRNA
by single-molecule ﬂuorescence in situ hybridization. Methods
Mol Biol 2015;1262:3–19.
[104] Lucks JB, Mortimer SA, Trapnell C, Luo S, Aviran S, Schroth
GP, et al. Multiplexed RNA structure characterization with
selective 20-hydroxyl acylation analyzed by primer extension
sequencing (SHAPE-Seq). Proc Natl Acad Sci U S A
2011;108:11063–8.
[105] Kertesz M, Wan Y, Mazor E, Rinn JL, Nutter RC, Chang HY,
et al. Genome-wide measurement of RNA secondary structure in
yeast. Nature 2010;467:103–7.
[106] Wan Y, Qu K, Ouyang Z, Chang HY. Genome-wide mapping of
RNA structure using nuclease digestion and high-throughput
sequencing. Nat Protoc 2013;8:849–69.
[107] Underwood JG, Uzilov AV, Katzman S, Onodera CS, Mainzer
JE, Mathews DH, et al. FragSeq: transcriptome-wide RNA
structure probing using high-throughput sequencing. Nat Meth-
ods 2010;7:995–1001.
[108] Han J, Zhang J, Chen L, Shen B, Zhou J, Hu B, et al. Efﬁcient
in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9.
RNA Biol 2014;11:829–35.
[109] Ho TT, Zhou N, Huang J, Koirala P, Xu M, Fung R, et al.
Targeting non-coding RNAs with the CRISPR/Cas9 system in
human cell lines. Nucleic Acids Res 2015;43:e17.[110] Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for
engineering biology. Nat Methods 2013;10:957–63.
[111] Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al.
RNA-guided human genome engineering via Cas9. Science
2013;339:823–6.
[112] Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE,
et al. CRISPR-mediated modular RNA-guided regulation of
transcription in eukaryotes. Cell 2013;154:442–51.
[113] Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK.
CRISPR RNA-guided activation of endogenous human genes.
Nat Methods 2013;10:977–9.
[114] Consortium F, the RP, Clst, Forrest AR, Kawaji H, Rehli M,
et al. A promoter-level mammalian expression atlas. Nature
2014;507:462–70.
[115] Cancer Genome Atlas Research N, Weinstein JN, Collisson EA,
Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome
Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113–20.
[116] Bhartiya D, Pal K, Ghosh S, Kapoor S, Jalali S, Panwar B, et al.
LncRNome: a comprehensive knowledgebase of human long
noncoding RNAs. Database 2013;2013:bat034.
[117] Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al.
LncRNADisease: a database for long-non-coding RNA-associ-
ated diseases. Nucleic Acids Res 2013;41:D983–6.
[118] Park C, Yu N, Choi I, Kim W, Lee S. LncRNAtor: a
comprehensive resource for functional investigation of long
non-coding RNAs. Bioinformatics 2014;30:2480–5.
[119] Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert
K, et al. LNCipedia: a database for annotated human lncRNA
transcript sequences and structures. Nucleic Acids Res 2013;41:
D246–51.
[120] Fritah S, Niclou SP, Azuaje F. Databases for lncRNAs: a
comparative evaluation of emerging tools. RNA
2014;20:1655–65.
[121] Dias N, Stein CA. Antisense oligonucleotides: basic concepts and
mechanisms. Mol Cancer Ther 2002;1:347–55.
[122] Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical phar-
macology and potential drug interactions. Clin Pharmacokinet
2002;41:255–60.
[123] Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM.
Antisense technology: an emerging platform for cardiovascular
disease therapeutics. J Cardiovasc Transl Res 2013;6:969–80.
[124] Zong X, Huang L, Tripathi V, Peralta R, Freier SM, Guo S,
et al. Knockdown of nuclear-retained long noncoding RNAs
using modiﬁed DNA antisense oligonucleotides. Methods Mol
Biol 2015;1262:321–31.
[125] Baldo BA. Enzymes approved for human therapy: indications,
mechanisms and adverse effects. BioDrugs 2015;29:31–55.
[126] Wahlestedt C. Targeting long non-coding RNA to therapeuti-
cally upregulate gene expression. Nat Rev Drug Discov
2013;12:433–46.
[127] Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP,
Magistri M, Brothers SP, et al. Inhibition of natural antisense
transcripts in vivo results in gene-speciﬁc transcriptional upreg-
ulation. Nat Biotechnol 2012;30:453–9.
[128] Sheridan C. RaNA therapeutics. Nat Biotechnol 2012;30:909.
[129] Sarma K, Levasseur P, Aristarkhov A, Lee JT. Locked nucleic
acids (LNAs) reveal sequence requirements and kinetics of Xist
RNA localization to the X chromosome. Proc Natl Acad Sci U S
A 2010;107:22196–201.
[130] Braasch DA, Corey DR. Locked nucleic acid (LNA): ﬁne-tuning
the recognition of DNA and RNA. Chem Biol 2001;8:1–7.
[131] Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al.
The nuclear-retained noncoding RNA MALAT1 regulates
alternative splicing by modulating SR splicing factor phospho-
rylation. Mol Cell 2010;39:925–38.
[132] Chen I, Chen CY, Chuang TJ. Biogenesis, identiﬁcation, and
function of exonic circular RNAs. Wiley Interdiscip Rev RNA
2015;6:563–79.
54 Genomics Proteomics Bioinformatics 14 (2016) 42–54[133] Mohammad F, Pandey GK, Mondal T, Enroth S, Redrup L,
Gyllensten U, et al. Long noncoding RNA-mediated mainte-
nance of DNA methylation and transcriptional gene silencing.
Development 2012;139:2792–803.
[134] Ounzain S, Micheletti R, Beckmann T, Schroen B, Alexanian M,
Pezzuto I, et al. Genome-wide proﬁling of the cardiac transcrip-
tome after myocardial infarction identiﬁes novel heart-speciﬁc
long non-coding RNAs. Eur Heart J 2015;36:353a–68a.
[135] Franke A, Baker BS. The rox1 and rox2 RNAs are essential
components of the compensasome, which mediates dosage
compensation in Drosophila. Mol Cell 1999;4:117–22.
[136] Gendrel AV, Heard E. Fifty years of X-inactivation research.
Development 2011;138:5049–55.
[137] Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M,
Tonlorenzi R, et al. A gene from the region of the human X
inactivation centre is expressed exclusively from the inactive X
chromosome. Nature 1991;349:38–44.
[138] Weakley SM, Wang H, Yao Q, Chen C. Expression and function
of a large non-coding RNA gene XIST in human cancer. World J
Surg 2011;35:1751–6.
[139] Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi
M. Highly upregulated in liver cancer noncoding RNA is
overexpressed in hepatic colorectal metastasis. Eur J Gastroen
Hepat 2009;21:688–92.
[140] Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, et al.
Elevation of highly up-regulated in liver cancer (HULC) by
hepatitis B virus X protein promotes hepatoma cell proliferation
via down-regulating p18. J Biol Chem 2012;287:26302–11.
[141] Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner
M, Strohmaier HM, et al. Characterization of HULC, a novel
gene with striking up-regulation in hepatocellular carcinoma, as
noncoding RNA. Gastroenterology 2007;132:330–42.
[142] Sirchia SM, Tabano S, Monti L, Recalcati MP, Gariboldi M,
Grati FR, et al. Misbehaviour of XIST RNA in breast cancer
cells. PLoS One 2009;4:e5559.
[143] Hu Y, Wang J, Qian J, Kong X, Tang J, Wang Y, et al. Long
noncoding RNA GAPLINC regulates CD44-dependent cell
invasiveness and associates with poor prognosis of gastric
cancer. Cancer Res 2014;74:6890–902.[144] Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al.
Long non-coding RNA MALAT-1 overexpression predicts
tumor recurrence of hepatocellular carcinoma after liver trans-
plantation. Med Oncol 2012;29:1810–6.
[145] Schmidt LH, Spieker T, Koschmieder S, Humberg J, Jungen D,
Bulk E, et al. The long noncoding MALAT-1 RNA indicates a
poor prognosis in non-small cell lung cancer and induces
migration and tumor growth. J Thorac Oncol 2011;6:1984–92.
[146] Xu CA, Yang MH, Tian J, Wang XY, Li ZG.MALAT-1: A long
non-coding RNA and its important 3 ’ end functional motif in
colorectal cancer metastasis. Int J Oncol 2011;39:169–75.
[147] Zhang J, Zhang B, Wang T, Wang H. LncRNA MALAT1
overexpression is an unfavorable prognostic factor in human
cancer: evidence from a meta-analysis. Int J Clin Exp Med
2015;8:5499–505.
[148] Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-
coding RNA HOTAIR is associated with hepatocellular carci-
noma progression. J Int Med Res 2011;39:2119–28.
[149] Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J,
Burghardt R, et al. HOTAIR is a negative prognostic factor and
exhibits pro-oncogenic activity in pancreatic cancer. Oncogene
2013;32:1616–25.
[150] Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H,
Takamaru H, et al. Upregulation of miR-196a and HOTAIR
drive malignant character in gastrointestinal stromal tumors.
Cancer Res 2012;72:1126–36.
[151] Yap KL, Li SD, Munoz-Cabello AM, Raguz S, Zeng L,
Mujtaba S, et al. Molecular interplay of the noncoding RNA
ANRIL and methylated histone H3 Lysine 27 by polycomb
CBX7 in transcriptional silencing of INK4a. Mol Cell
2010;38:662–74.
[152] Chung SY, Nakagawa H, Uemura M, Piao L, Ashikawa K,
Hosono N, et al. Association of a novel long non-coding RNA in
8q24 with prostate cancer susceptibility. Cancer Sci
2011;102:245–52.
[153] Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-Iail R,
Hochberg A, et al. The H19 non-coding RNA is essential for
human tumor growth. PLoS One 2007;2:e845.
